{"id":378680,"date":"2023-12-12T12:00:38","date_gmt":"2023-12-12T17:00:38","guid":{"rendered":"https:\/\/platohealth.ai\/a-targeted-therapy-shows-it-can-offer-a-last-great-chance-for-some-acute-leukemia-patients\/"},"modified":"2023-12-13T00:00:50","modified_gmt":"2023-12-13T05:00:50","slug":"a-targeted-therapy-shows-it-can-offer-a-last-great-chance-for-some-acute-leukemia-patients","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/a-targeted-therapy-shows-it-can-offer-a-last-great-chance-for-some-acute-leukemia-patients\/","title":{"rendered":"A targeted therapy shows it can offer a \u2018last, great chance\u2019 for some acute leukemia patients","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

S<\/span><\/span>AN DIEGO \u2014 One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don\u2019t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.<\/p>\n

The study, called the Phase 2 Augment-101 trial, tested Syndax\u2019s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study\u2019s presenter, in an interview.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

\u201cKMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,\u201d Aldoss said. \u201cThe median overall survival remains low with current available treatment. Right now there\u2019s no targeted therapy for KMT2A-rearranged disease. We\u2019re really excited about revumenib as it targets the mutation, and we\u2019re seeing encouraging outcomes.\u201d<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n